Share on LinkedInShare on LinkedIn

ARTICLE · 16 JUNE 2004

A Prescription for Follow-on Biologics?

As can be seen from other recent articles, changes have recently been made to the route for marketing authorisation for pharmaceuticals in the European Community. These rules are not restricted to standard chemical pharmaceuticals, and this article will address the new rules relating to marketing authorisations for "follow-on" biological medicinal products.

European UnionAntitrust/Competition Law
Paul Brown
Paul Brown

INTRODUCTION

As can be seen from other recent articles, changes have recently been made to the route for marketing authorisation for pharmaceuticals in the European Community. These rules are not restricted to standard chemical pharmaceuticals, and this article will address the new rules relating to marketing authorisations for "follow-on" biological medicinal products.

WHAT IS A BIOLOGIC?

For the purposes of this article the word "biologic" will be used to refer to a biological medicinal product, which is the term used in the legislation. There is no comprehensive legal definition of what a biologic is, but it is generally agreed that a biologic is a medicine that can only be made using a living system or organism, and that contains a substance that has documented biological activity.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from